Table 4.
Characteristics of the patients with gastric adenocarcinoma and esophageal squamous cell cancer.
| Variables | Gastric adenocarcinoma | Esophageal squamous cell carcinoma | ||||||
|---|---|---|---|---|---|---|---|---|
| Total | Low IL-6 | High IL-6 | p | Total | Low IL-6 | High IL-6 | p | |
| Total | 79 | 42 | 37 | 42 | 24 | 18 | 0.676 | |
| Gender | ||||||||
| Female | 24 (30.4) | 15 (35.7) | 9 (24.3) | 10 (23.8) | 6 (25.0) | 4 (22.2) | ||
| Male | 55 (69.6) | 27 (64.3) | 28 (75.7) | 0.272 | 32 (76.2) | 18 (75.0) | 14 (77.8) | 1.000 |
| Age | ||||||||
| ≥ 65 | 42 (53.2) | 20 (45.0) | 17 (45.9) | 25 (59.5) | 16 (66.7) | 9 (50.0) | ||
| < 65 | 37 (46.8) | 22 (55.0) | 20 (54.1) | 0.882 | 17 (40.5) | 8 (33.3) | 9 (50.0) | 0.276 |
| ECOG PS | ||||||||
| ≤ 2 | 64 (81.0) | 31 (73.8) | 33 (89.2) | 40 (95.2) | 22 (91.7) | 18 (100) | ||
| ≥ 3 | 15 (19.0) | 11 (26.2) | 4 (10.8) | 0.082 | 2 (4.8) | 2 (8.3) | 0 (0.0) | 0.601 |
| TNM | ||||||||
| III | 29 (36.7) | 21 (50.0) | 8 (21.6) | 24 (57.1) | 12 (50.0) | 12 (66.7) | ||
| IV | 50 (63.3) | 21 (50.0) | 29 (78.4) | 0.009* | 18 (42.9) | 12 (50.0) | 6 (33.3) | 0.280 |
| Surgery history | ||||||||
| No | 51 (64.6) | 26 (61.9) | 25 (67.6) | 29 (69.0) | 19 (79.2) | 10 (55.6) | ||
| Yes | 28 (35.4) | 16 (38.1) | 12 (32.4) | 0.600 | 13 (31.0) | 5 (20.8) | 8 (44.4) | 0.101 |
| Thrapy | ||||||||
| ICIs monotherapy | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (4.8) | 1 (4.2) | 1 (5.6) | ||
| ICIs & chemotherapy | 53 (67.1) | 27 (64.3) | 26 (70.3) | 38 (90.5) | 22 (91.7) | 16 (88.9) | ||
| ICIs & targeted | 12 (15.2) | 7 (16.7) | 5 (13.5) | 1 (2.4) | 0 (0.0) | 1 (5.6) | ||
| Triple therapy | 14 (17.7) | 8 (19.0) | 6 (16.2) | 0.851 | 1 (2.4) | 1 (4.2) | 0 (0.0) | 0.545 |
| Treatment lines | ||||||||
| 1-2 | 67 (84.8) | 37 (88.1) | 30 (81.1) | 39 (92.9) | 23 (95.8) | 16 (88.9) | ||
| ≥3 | 12 (15.2) | 5 (11.9) | 7 (18.9) | 0.386 | 3 (7.1) | 1 (4.2) | 2 (11.1) | 0.795 |
| irAEs | ||||||||
| No | 36 (45.6) | 24 (57.1) | 12 (32.4) | 20 (47.6) | 15 (62.5) | 5 (27.8) | ||
| Yes | 43 (54.4) | 18 (42.9) | 25 (67.6) | 0.028* | 22 (52.4) | 9 (37.5) | 13 (72.2) | 0.026* |
ECOG PS, Eastern Cooperative Oncology Group performance status; ICIs, Immune checkpoint inhibitors; Triple therapy, immunotherapy combination chemotherapy with targeted therapy; irAEs, immune-related adverse events; HR, hazard ratio; CI, confidence interval. *p < 0.05.